Reversible dementia causes are all except-
Global cerebral dysfunction characterised by alteration in cognitive function and consciousness is known as
Which of the following is the most appropriate treatment for an overactive bladder in a patient with dementia?
True about dementia is:
A 60-year-old woman has recurrent falls, visual hallucinations, and fluctuating cognition. Exam shows parkinsonism. What is the most likely diagnosis?
Subcortical dementia is seen in all except :
All of the following are Anticholinesterases used in Alzheimer's disease except
Which of the following non-memory cognitive symptoms can be associated with Alzheimer's disease (AD)?
Dementia is present in all except:
Which of the following is NOT a feature of dementia?
Explanation: ***Lewy body dementia*** - **Lewy body dementia** is a **progressive neurodegenerative disease**, characterized by the abnormal accumulation of alpha-synuclein proteins (Lewy bodies) in the brain. - It is an **irreversible form of dementia**, meaning its cognitive decline cannot be halted or reversed. *Subdural hematoma* - A **subdural hematoma**, especially chronic, can cause **cognitive impairment** due to pressure on the brain [1]. - If diagnosed and treated early (e.g., surgical evacuation), the associated cognitive deficits can often be **reversed or significantly improved**. *Myxedema* - **Myxedema**, or severe hypothyroidism, can lead to **reversible cognitive dysfunction**, including memory impairment and slowed thinking. - Treatment with **thyroid hormone replacement** can reverse the dementia-like symptoms. *Vitamin B12 deficiency* - **Vitamin B12 deficiency** can cause a range of neurological symptoms, including **cognitive decline** and dementia-like symptoms [1]. - With timely and adequate **vitamin B12 supplementation**, the associated cognitive impairment can often be **reversed** [1].
Explanation: ***Delirium*** - Delirium is characterized by an **acute onset** of global cerebral dysfunction, marked by fluctuations in **attention, consciousness, and cognition**. - It is a medical emergency that can be caused by various underlying medical conditions, medications, or substance withdrawal. *Dementia* - Dementia is a **chronic** and progressive decline in cognitive function, primarily affecting **memory, language, and problem-solving abilities**, without a primary disturbance of consciousness. - While it involves cognitive impairment, its onset is typically gradual, and it lacks the acute fluctuations and prominent consciousness alterations seen in delirium. *Depression* - Depression is a **mood disorder** characterized by persistent sadness, loss of interest, and other emotional and physical symptoms, which can affect concentration and memory. - It does not involve a primary alteration in consciousness or the acute, global cognitive dysfunction characteristic of delirium. *Acute anxiety* - Acute anxiety is a state of intense fear or uneasiness, often accompanied by physical symptoms like palpitations and shortness of breath. - While it can interfere with focus and concentration, it does not represent a global cerebral dysfunction or an alteration in consciousness in the way that delirium does.
Explanation: ***Tolterodine*** - **Tolterodine** is a **muscarinic antagonist** that blocks acetylcholine receptors in the bladder, reducing detrusor muscle contractions and overactive bladder symptoms. - Unlike some other anticholinergics like oxybutynin, it has a **lower propensity to cross the blood-brain barrier** and thus a reduced risk of exacerbating cognitive impairment in patients with dementia. *Mirabegron* - **Mirabegron** is a **beta-3 adrenergic agonist** that relaxes the detrusor muscle, increasing bladder capacity. - While it has a different mechanism of action and is less likely to cause anticholinergic cognitive side effects than older anticholinergics, it can still cause **hypertension** and **tachycardia**, which may be problematic in elderly patients with comorbidities. *Behavioral therapy/bladder training* - **Behavioral therapy** and **bladder training** are important first-line treatments for overactive bladder. - However, for patients with **dementia**, cognitive impairment often makes adherence to and understanding of these complex therapies challenging or impossible without significant caregiver support. *Oxybutynin* - **Oxybutynin** is an **anticholinergic drug** that is effective for overactive bladder. - However, it has a **high affinity for muscarinic receptors** in the brain and readily crosses the blood-brain barrier, significantly increasing the risk of **cognitive impairment, confusion, and delirium** in elderly patients, especially those with pre-existing dementia. *Trospium* - **Trospium** is a **quaternary amine anticholinergic** that is hydrophilic and has minimal blood-brain barrier penetration. - While theoretically safer than oxybutynin in terms of CNS effects, it has **lower bladder selectivity** compared to tolterodine and may cause more peripheral anticholinergic side effects (dry mouth, constipation).
Explanation: ***Dementia involves a decline in memory and other cognitive functions affecting daily living*** - This statement accurately defines **dementia** as a significant decline in **cognitive functions**, including memory, language, problem-solving, and executive function, severe enough to interfere with daily activities. - The progressive nature of this decline leads to impaired independence and functional disability. *Dementia due to atherosclerosis progresses in the same gradual manner as Alzheimer's disease* - **Vascular dementia**, often caused by atherosclerosis leading to stroke or chronic cerebral ischemia, typically has a **stepped or fluctuating progression** rather than the gradual, continuous decline seen in Alzheimer's disease. - This is a key distinguishing feature between vascular dementia and Alzheimer's disease. *Alzheimer's disease is due to multiple small strokes in the cerebral cortex* - This describes **vascular dementia**, which is distinct from Alzheimer's disease. - **Alzheimer's disease** is characterized by the accumulation of **amyloid plaques** and **neurofibrillary tangles** in the brain, not by strokes. *Alzheimer's disease is associated with an increase in ACh release in the cerebral cortex* - **Alzheimer's disease** is associated with a significant **reduction in acetylcholine (ACh) levels** in the cerebral cortex, particularly in regions vital for memory and learning. - Many treatments for Alzheimer's aim to inhibit **acetylcholinesterase**, thereby increasing ACh availability to compensate for this deficit.
Explanation: ***Lewy body dementia*** - This condition is characterized by a classic triad of symptoms: **fluctuating cognition**, recurrent **visual hallucinations**, and **parkinsonism**. - **Recurrent falls** are also a common feature, stemming from severe **postural instability** and motor fluctuations. *Alzheimer’s disease* - The hallmark of Alzheimer's disease is **progressive memory loss** and cognitive decline [1], without prominent early **visual hallucinations** or marked **parkinsonism**. - While falls can occur in later stages, they are not typically an early or recurrent feature to the same extent as in Lewy body dementia. *Parkinson’s disease* - Parkinson's disease primarily presents with **motor symptoms** such as **bradykinesia**, **rigidity**, **tremor**, and **postural instability** [2]. - Dementia and hallucinations can develop, but they usually occur much later in the disease course, often after years of established motor symptoms [3]. *Vascular dementia* - This type of dementia is characterized by a **stepwise decline** in cognitive function, often associated with a history of **strokes** or **cardiovascular risk factors**. - While it can cause cognitive fluctuations and falls, **visual hallucinations** and prominent **parkinsonism** are not typical early features.
Explanation: ***Alzheimer's disease*** - Alzheimer's disease is primarily a **cortical dementia**, characterized by the impairment of higher cognitive functions like memory, language, and executive function due to degeneration of the cerebral cortex [1]. - While it can later affect subcortical structures, its hallmark features are related to cortical pathology, such as **neurofibrillary tangles** and amyloid plaques primarily in cortical regions [1]. *Wilson's disease* - Wilson's disease is a genetic disorder of **copper metabolism** that leads to copper accumulation in the brain, liver, and other organs. - The basal ganglia, a key subcortical structure, is particularly vulnerable to copper toxicity, leading to prominent **movement disorders** and **subcortical dementia**. *Huntington's Chorea* - Huntington's disease is a progressive neurodegenerative disorder characterized by the degeneration of neurons in the **basal ganglia** (especially the striatum) and cerebral cortex. - The significant involvement of the basal ganglia leads to the characteristic **chorea** and **subcortical dementia** with cognitive slowing and executive dysfunction. *Parkinsonism* - Parkinsonism, particularly Parkinson's disease, is characterized by the degeneration of dopaminergic neurons in the **substantia nigra pars compacta**, a subcortical structure. - This leads to motor symptoms and frequently also to **subcortical executive dysfunction** and slower processing speed, consistent with a subcortical dementia.
Explanation: ***Memantine*** - While used in Alzheimer's disease, **memantine** is an **NMDA receptor antagonist**, not an anticholinesterase. - It works by blocking excessive **glutamatergic stimulation**, which is implicated in neurodegeneration. *Donepezil* - **Donepezil** is an **acetylcholinesterase inhibitor** used to treat mild to moderate Alzheimer's disease. - It increases the availability of **acetylcholine** in the synaptic cleft, improving cognitive function. *Rivastigmine* - **Rivastigmine** is a **cholinesterase inhibitor** that acts on both **acetylcholinesterase** and **butyrylcholinesterase**. - It is approved for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia. *Galantamine* - **Galantamine** is an **acetylcholinesterase inhibitor** and an **allosteric potentiator of nicotinic acetylcholine receptors**. - It enhances cholinergic neurotransmission and is used in the treatment of mild to moderate Alzheimer's disease.
Explanation: ***All of the options*** - Alzheimer's disease is characterized by a decline in various cognitive domains, extending beyond memory impairment to include **aphasia**, **apraxia**, and **agnosia**. - These non-memory symptoms become increasingly prominent as the disease progresses and are essential for a comprehensive diagnostic evaluation. *Aphasia* - **Aphasia**, or difficulty with language production or comprehension, is a common non-memory cognitive symptom in AD. - Patients may struggle to find words, understand spoken or written language, or produce coherent sentences. *Apraxia* - **Apraxia**, the inability to perform learned motor movements despite intact motor function and comprehension, is frequently observed in AD. - This can manifest as difficulty with activities of daily living, such as dressing, eating, or using tools. *Agnosia* - **Agnosia**, the inability to recognize objects, people, sounds, shapes, or smells despite intact sensory function, is another non-memory cognitive deficit seen in AD. - Patients may not recognize familiar faces or common household items.
Explanation: ***Ganser syndrome*** - Ganser syndrome is a **factitious disorder** characterized by approximate answers, not true dementia. - Patients with Ganser syndrome often present with dramatic, but ultimately **nonsensical responses** to simple questions, without a clear underlying organic cause of cognitive decline. *Lewy body* - **Lewy body dementia** is characterized by fluctuating cognition, recurrent visual hallucinations, and spontaneous parkinsonism. - It involves the presence of **Lewy bodies** in cortical and subcortical regions leading to progressive cognitive decline. *Pick's disease* - Pick's disease, a type of frontotemporal dementia, is characterized by language and **behavioral changes** due to neuronal loss. - It results in progressive **atrophy of the frontal and temporal lobes**, leading to profound cognitive deficits over time. *Alzheimer's disease* - **Alzheimer's disease** is the most common cause of dementia, characterized by progressive memory loss and cognitive impairment. - It is pathologically defined by the presence of **amyloid plaques** and **neurofibrillary tangles** in the brain.
Explanation: ***Loss of sensorium*** - **Loss of sensorium** refers to a decreased level of consciousness or awareness, which is characteristic of **delirium**, not dementia. - In dementia, consciousness and arousal are typically preserved until the very late stages of the disease. *Wearing of dirty clothes* - **Neglect of personal hygiene**, such as wearing dirty clothes, is a common feature of dementia due to impaired judgment, memory, and executive function. - Individuals with dementia may forget to change clothes, bathe, or groom themselves. *Disturbances in language function* - **Aphasia**, or disturbances in language function (e.g., difficulty finding words, understanding speech), is a hallmark feature of many types of dementia. - This can impact both expressive and receptive language abilities as the disease progresses. *Loss of neurons in brain* - **Neurodegeneration**, involving the **loss of neurons** in specific brain regions, is the underlying pathological basis of all types of dementia. - This neuronal loss leads to brain atrophy and the cognitive and functional impairments observed in dementia.
Get full access to all questions, explanations, and performance tracking.
Start For Free